Allogene Therapeutics to Report First Quarter Financial Results on May 5, 2021
Allogene Therapeutics is set to release its first quarter 2021 financial results on May 5, 2021, after market close. Following this, a live audio webcast and conference call will take place at 2:00 PM PT (5:00 PM ET). The company specializes in developing allogeneic CAR T therapies for cancer, aiming to provide scalable, accessible treatments. The webcast will be available on their website, www.allogene.com, with a replay option for 30 days. The release includes cautionary forward-looking statements regarding company projections and financial reporting.
- Scheduled financial results report on May 5, 2021, indicating transparency.
- Development of 'off-the-shelf' CAR T therapies could meet increasing demand in cancer treatment.
- None.
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time/5:00 PM Eastern Time.
Audio Webcast
The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
Dial-In Information
Live (U.S. / Canada): 1 (866) 940-5062
Live (International): 1 (409) 216-0618
Conference ID: 9435559
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and ability to report financial results, the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-K for the year ended December 31, 2020. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com
FAQ
When will Allogene Therapeutics report its first quarter 2021 financial results?
What time is the Allogene Therapeutics conference call scheduled?
Where can I listen to the Allogene Therapeutics webcast?
What is the focus of Allogene Therapeutics?
